Association of neurocognitive impairment and financial hardship in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).

D Daniel J. Zheng S Shalini Bhatia (St. Jude Childrens Research Hospital, Memphis, TN) S Sedigheh Mirzaei (1St. Jude Children's Research Hospital, Memphis, United States) Y Yutaka Yasui S Sogol Mostoufi-Moab (Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, PA) K Kira Bona (5Dana-Farber Cancer Institute, Boston, United States) K Kelly Getz (1University of Pennsylvania, Department of Biostatistics, Epidemiology and Informatics, Philadelphia, United States) R Richard Aplenc R Robin Yabroff (American Cancer Society, Atlanta, GA) I I-Chan Huang (St. Jude Children's Research Hospital, Memphis, TN) P Pim Brouwers (National Institutes of Health, Rockville, MD) T Tara M. Brinkman K Kim Edelstein (Princess Margaret - University Health Network, Toronto, ON, Canada) E Elyse Richelle Park (Health Promotion and Resilience Intervention Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA) A Anne C. Kirchhoff (Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT) G Gregory T. Armstrong C Claire Frances Snyder (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD) K Kevin R. Krull P Paul C. Nathan

Abstract

10055 Background: Adult survivors of childhood cancer are at high risk for financial hardship due to the cumulative lifetime costs of cancer-directed therapy and chronic health conditions. Whether neurocognitive impairment increases the risk for financial hardship is unknown. Methods: Childhood cancer survivors (≥ 5-year survivors, diagnosed < 21 years of age between 1970-1999) enrolled in CCSS completed a validated self-report Neurocognitive Questionnaire (NCQ) in 2014 and a subsequent financial hardship survey (age ≥ 26 at survey completion) 3 years later. The NCQ measured neurocognitive impairment in four domains: (1) memory ; (2) task efficiency; (3) organization; (4) emotional regulation. NCQ was the exposure and operationalized as the number of impaired domains (0-4); in each domain, impairment was defined as a Z-score >90 th percentile. Financial hardship outcomes were measured in behavioral (e.g., delaying care due to cost), material (e.g., high out-of-pocket costs), and psychological (e.g., worry about financial situation) domains, as well as two discrete outcomes of debt collection and bankruptcy. Multivariable linear and logistic regressions were used to analyze associations adjusting for age, sex, and race/ethnicity. Results: 3023 survivors completed the NCQ (mean age 38.8, SD=8.6 years) and a subsequent financial hardship survey (mean age 41.5, SD=8.7 years). 13.9%, 8.1%, 6.0%, and 2.6% of survivors had neurocognitive impairments in 1-4 domains, respectively. Individuals with NCQ impairment had significantly higher mean standardized scores across all three financial hardship domains than those without NCQ impairments (Table). Each ordinal increase in the number of impaired NCQ domains was associated with a higher mean standardized score for both behavioral and material financial hardship. Individuals with impairments in all four NCQ domains were more likely to be sent to debt collection (54% vs. 25%, OR=3.82, 95% CI: 2.27-6.43) and file for bankruptcy protection (21% vs. 8%, OR=2.81, 95% CI: 1.53-5.17) compared to those without impairments. Conclusions: Cancer survivors with neurocognitive impairment are particularly vulnerable to financial hardship. This survivor population should be specifically assessed for these outcomes and offered support to prevent and mitigate financial challenges. Standardized mean differences (SMD) of each financial hardship domain by number of NCQ impairments compared to no NCQ impairments. Number of NCQ domains impaired Behavioral Domain SMD (95% CI) Material DomainSMD (95% CI) Psychological DomainSMD (95% CI) 1 0.21 (0.11-0.31) 0.20 (0.10-0.29) 0.41 (0.31-0.50) 2 0.39 (0.27-0.51) 0.32 (0.20-0.44) 0.38 (0.25-0.50) 3 0.48 (0.34-0.63) 0.35 (0.20-0.49) 0.44 (0.30-0.58) 4 0.72 (0.51-0.93) 0.72 (0.52-0.94) 0.74 (0.53-0.94)

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 10055-10055
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (19)

D

Daniel J. Zheng

S

Shalini Bhatia

St. Jude Childrens Research Hospital, Memphis, TN

S

Sedigheh Mirzaei

1St. Jude Children's Research Hospital, Memphis, United States

Y

Yutaka Yasui

S

Sogol Mostoufi-Moab

Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, PA

K

Kira Bona

5Dana-Farber Cancer Institute, Boston, United States

K

Kelly Getz

1University of Pennsylvania, Department of Biostatistics, Epidemiology and Informatics, Philadelphia, United States

R

Richard Aplenc

R

Robin Yabroff

American Cancer Society, Atlanta, GA

I

I-Chan Huang

St. Jude Children's Research Hospital, Memphis, TN

P

Pim Brouwers

National Institutes of Health, Rockville, MD

T

Tara M. Brinkman

K

Kim Edelstein

Princess Margaret - University Health Network, Toronto, ON, Canada

E

Elyse Richelle Park

Health Promotion and Resilience Intervention Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA

A

Anne C. Kirchhoff

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

G

Gregory T. Armstrong

C

Claire Frances Snyder

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD

K

Kevin R. Krull

P

Paul C. Nathan